earnings
confidence high
sentiment positive
materiality 0.85
Biogen Q4 revenue $2.3B, GAAP EPS loss $(0.33); FY2025 Non-GAAP EPS $15.28 beats guidance
BIOGEN INC.
2025-FY EPS
reported $8.79
vs consensus $1.65
▲ beat
(+433.9%)
- Q4 total revenue $2.3B (-7% YoY); GAAP diluted EPS $(0.33); Non-GAAP diluted EPS $1.99.
- Full year total revenue $9.9B (+2% YoY); GAAP diluted EPS $8.79; Non-GAAP EPS $15.28 above $14.50-$15.00 guidance.
- Growth products up 6% YoY in Q4; LEQEMBI global in-market sales $134M (+54% YoY).
- FY2026 guidance: Non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit percent vs FY2025.
- Pipeline: LEQEMBI subcutaneous PDUFA May 24, 2026; litifilimab Breakthrough Therapy for CLE; high-dose SPINRAZA PDUFA Apr 3.